{"id":4498,"date":"2025-03-31T18:12:10","date_gmt":"2025-03-31T18:12:10","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/domperidone-txt\/"},"modified":"2025-03-31T18:12:10","modified_gmt":"2025-03-31T18:12:10","slug":"domperidone-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/domperidone-txt\/","title":{"rendered":"domperidone .txt"},"content":{"rendered":"

domperidone <\/h1>\n

CLINICAL USE <\/H3>
\nAnti-emetic:Cancer chemotherapy Postoperative nausea and vomiting (PONV)

DOSE IN NORMAL RENAL FUNCTION <\/H3>Chemotherapy: IV bolus or infusion: 100 mg \u201430 minutes before chemotherapyOral: 200 mg 1 hour before \u2014chemotherapy, then 200 mg daily to prevent delayed nausea and vomitingPONV: IV bolus or infusion: 12.5 mg \u2014Oral: 50 mg before induction of \u2014anaesthesia

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :420.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :69\u201377<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50\u201360<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :5\u20137.9<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :7\u20139\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAnti-arrhythmics: increased risk of ventricular arrhythmias \u2013 avoid concomitant useBeta-blockers: increased risk of ventricular arrhythmias with sotalol \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4>Oral, IV bolus,

    IV infusion <\/H4>

    Rate of Administration <\/H4>Bolus: over 30 seconds Infusion: over 15 minutes

    Comments<\/H4>Can be added to 50 mL sodium chloride 0.9%, glucose 5% or compound sodium lactate

    OTHER INFORMATION <\/H4>Peak concentrations occur 1 hour after oral and 0.6 hour after IV dosesOral bioavailability of 75% Active metabolite is renally excreted (approximately 30%)In patients with severe renal impairment (creatinine clearance
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min), maximum plasma levels of metabolite are increased 17% or 34%, respectively, after intravenous or oral administration of dolasetron, and systemic exposure is increased approximately 2-fold dolasetron mesilate.
    \n","protected":false},"excerpt":{"rendered":"

    domperidone CLINICAL USE Anti-emetic:Cancer chemotherapy Postoperative nausea and vomiting (PONV)<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4498","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4498"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4498\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}